Pivotal Study For PSD502 — The First Potential Treatment For Premature Ejaculation (redOrbit)

On-demand aerosol spray increased ejaculatory latencyAt the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC (“Plethora” – AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment …

Read the rest here:
Pivotal Study For PSD502 — The First Potential Treatment For Premature Ejaculation (redOrbit)